---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008882"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:28:07.337551+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Phase 3 uproleselan misses primary OS endpoint; positive subgroup in primary refractory AML

## Summary
- Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.
- In primary refractory AML (n=128), mOS improved to 31.2 vs 10.1 months (HR 0.58; 95% CI 0.37-0.91).
- Safety consistent with chemotherapy; no new adverse event signals.
- Company planning to engage regulators and NCI; Phase 2/3 study in frontline AML advancing.

## SEC filing metadata
- accession: 0001558370-24-008882
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/0001558370-24-008882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/glyc-20240604x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008882
- JSON: https://secwatch.observer/filing/0001558370-24-008882.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.